Akums Drugs And Pharmaceuticals IPO All You Need To Know - NDTV Profit
| AKUMS Stock | 576.45 0.90 0.16% |
About 55% of Akums Drugs' investor base is interested to short. The analysis of the overall prospects from investing in Akums Drugs and suggests that many traders are, at the present time, impartial. Akums Drugs' investing sentiment overview a quick insight into current market opportunities from investing in Akums Drugs and. Many technical investors use Akums Drugs stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Akums |
Akums Drugs And Pharmaceuticals IPO All You Need To Know NDTV Profit
Read at news.google.com
 |
Akums Drugs Fundamental Analysis
We analyze Akums Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Akums Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Akums Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
Akums Drugs is rated third in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Akums Drugs Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Akums Drugs stock to make a market-neutral strategy. Peer analysis of Akums Drugs could also be used in its relative valuation, which is a method of valuing Akums Drugs by comparing valuation metrics with similar companies.
Peers
Akums Drugs Related Equities
| AKUMS | Akums Drugs | 0.16 |
| ||
| INNOVACAP | Innova Captab | 0.95 |
| ||
| ALIVUS | Alivus Life | 2.10 |
| ||
| EMCURE | Emcure Pharmaceuticals | 3.15 |
|
Other Information on Investing in Akums Stock
Akums Drugs financial ratios help investors to determine whether Akums Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Akums with respect to the benefits of owning Akums Drugs security.